November 3, 2021 – Medela LLC announced the release of new data in a white paper supplement to WOUNDS demonstrating the Medela Invia Liberty Negative Pressure Wound Therapy (NPWT) System outperforms other multi-lumen NPWT systems available in the market.
Medela’s patented Intelligent Pressure Control and Dynamic Exudate Removal technology ensures the prescribed pressure is reliably delivered at the wound bed while dynamically responding to fluctuations in fluid volume and viscosity; essential to prevent blockages and promote efficient fluid removal to maximize the clinical effectiveness.
According to the company, the published data demonstrates how Medela’s Invia Liberty NPWT System was able to clear 89% of the fluid bolus challenge and re-establish the prescribed pressure in less than 20 minutes.
Comparatively, the Cardinal CATALYST (Cardinal Health), failed to remove any detectable level of fluid throughout the entire two-hour study duration and had pressure readings that consistently fluctuated > 10% above the set pressure level. The results from this investigation confirm the patented Intelligent Pressure Control and Dynamic Exudate Removal technology, available exclusively to Medela, allowed the system to remove exudate more efficiently and return to the prescribed pressure more expeditiously after a bolus challenge to deliver therapy more effectively.
In 2020, the Medela Invia NPWT Systems were awarded an Innovative Technology contract from Vizient, Inc. (Irving, TX).